NASDAQ:FENC

Fennec Pharmaceuticals - FENC Stock Forecast, Price & News

$7.04

-0.04 (-0.56%)

(As of 08/11/2022 12:00 AM ET)

Add

Compare

Today's Range: $6.81
▼
$7.25
50-Day Range: $5.31
▼
$7.08
52-Week Range: $3.37
▼
$7.59

Volume: 44,666 shs
Average Volume: 38,369 shs
Market Capitalization: $183.64 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $12.00

Fennec Pharmaceuticals MarketRank™ Forecast

Analyst Rating: Moderate Buy
2.75 Rating Score
Upside/Downside: 70.3% Upside
$12.00 Price Target
Short Interest: Bearish
0.86% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.56
Based on 8 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($0.45) to ($0.23) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.86 out of 5 stars

Medical Sector

869th out of 1,112 stocks

Biological Products, Except Diagnostic Industry

140th out of 175 stocks

3.4

Analyst's Opinion

Consensus Rating
Fennec Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 2.75, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $12.00, Fennec Pharmaceuticals has a forecasted upside of 70.3% from its current price of $7.05.
Amount of Analyst Coverage
Fennec Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.

2.0

Short Interest

Percentage of Shares Shorted
0.86% of the float of Fennec Pharmaceuticals has been sold short.
Short Interest Ratio / Days to Cover
Fennec Pharmaceuticals has a short interest ratio ("days to cover") of 6.3.
Change versus previous month
Short interest in Fennec Pharmaceuticals has recently increased by 18.33%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Fennec Pharmaceuticals does not currently pay a dividend.
Dividend Growth
Fennec Pharmaceuticals does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for FENC.

2.5

News and Social Media Coverage

News Sentiment
Fennec Pharmaceuticals has a news sentiment score of 0.56. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
News Coverage This Week
MarketBeat has tracked 8 news articles for Fennec Pharmaceuticals this week, compared to 1 article on an average week.
MarketBeat Follows
3 people have added Fennec Pharmaceuticals to their MarketBeat watchlist in the last 30 days.

0.8

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Fennec Pharmaceuticals insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 9.68% of the stock of Fennec Pharmaceuticals is held by insiders.
Percentage Held by Institutions
43.62% of the stock of Fennec Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Fennec Pharmaceuticals are expected to grow in the coming year, from ($0.45) to ($0.23) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Fennec Pharmaceuticals is -11.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Fennec Pharmaceuticals is -11.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Fennec Pharmaceuticals has a P/B Ratio of 11.55. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Fennec Pharmaceuticals (NASDAQ:FENC) Stock

Fennec Pharmaceuticals Inc., a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was founded in 1996 and is based in Research Triangle Park, North Carolina.

Fennec Pharmaceuticals Stock Down 0.5 %

NASDAQ:FENC traded down $0.04 during trading hours on Thursday, reaching $7.05. 44,666 shares of the company were exchanged, compared to its average volume of 38,369. The company has a debt-to-equity ratio of 0.36, a quick ratio of 8.96 and a current ratio of 8.96. The stock's 50-day moving average is $6.17 and its 200-day moving average is $5.74. Fennec Pharmaceuticals has a twelve month low of $3.37 and a twelve month high of $7.59.

Fennec Pharmaceuticals (NASDAQ:FENC - Get Rating) last issued its earnings results on Thursday, May 12th. The company reported ($0.14) EPS for the quarter, missing analysts' consensus estimates of ($0.13) by ($0.01). Research analysts expect that Fennec Pharmaceuticals will post -0.45 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of analysts recently issued reports on FENC shares. Craig Hallum reissued a "buy" rating and set a $14.00 price target on shares of Fennec Pharmaceuticals in a report on Monday. Wedbush restated an "outperform" rating on shares of Fennec Pharmaceuticals in a research report on Wednesday, April 27th.

Receive FENC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Fennec Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

FENC Stock News Headlines

August 11, 2022 | americanbankingnews.com

Fennec Pharmaceuticals (NASDAQ:FENC) Receives "Buy" Rating from Craig Hallum

August 1, 2022 | finance.yahoo.com

RTP drugmaker secures up to $45M despite regulatory speed bumps

May 12, 2022 | finance.yahoo.com

Fennec Pharmaceuticals Announces First Quarter 2022 Financial Results and Provides Business Update

May 6, 2022 | finance.yahoo.com

Inflation crushes market caps of Triangle's biggest public companies – except these ones

May 3, 2022 | finance.yahoo.com

Can Adherex Technologies Inc. (FENC) Climb 92% to Reach the Level Wall Street Analysts Expect?

April 27, 2022 | seekingalpha.com

Fennec refiling gets FDA review for Pedmark to prevent chemotherapy-induced hearing loss in children

April 27, 2022 | finance.yahoo.com

Fennec Pharmaceuticals Announces FDA Acceptance for Filing of New Drug Application Resubmission for PEDMARK™

April 5, 2022 | baystreet.ca

The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of TLS, FENC and ASTR

March 28, 2022 | benzinga.com

The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of FENC, CRNC and CABA

March 25, 2022 | bizjournals.com

After two rejections and no revenue, Fennec again seeks FDA approval

March 25, 2022 | finance.yahoo.com

Fennec Pharmaceuticals to Participate in the 2022 Maxim Virtual Growth Conference

March 24, 2022 | nasdaq.com

Fennec Resubmits Pedmark NDA To FDA

March 24, 2022 | marketwatch.com

Fennec Pharmaceuticals Files Again for FDA OK of Pedmark >FENC

March 24, 2022 | seekingalpha.com

Fennec refiles for FDA approval of Pedmark for preventing ototoxicity due to chemotherapy

March 11, 2022 | benzinga.com

SHAREHOLDER ALERT: EHTH ELMS FENC: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines

March 11, 2022 | benzinga.com

The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of ELMS, FENC and MP

March 8, 2022 | benzinga.com

The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of ELMS, FENC and ERIC

March 8, 2022 | benzinga.com

The Gross Law Firm Announces Class Actions on Behalf of Shareholders of ELMS, TLS and FENC

March 5, 2022 | benzinga.com

ROSEN, A TOP RANKED LAW FIRM, Encourages Fennec...

March 4, 2022 | benzinga.com

CLASS ACTION UPDATE for ELMS, FENC and GATO: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

March 4, 2022 | apnews.com

DEADLINE ALERT for FENC, AFIB, SPWR, and PLSE: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders

March 2, 2022 | benzinga.com

CLASS ACTION UPDATE for OSH, ELMS and FENC: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

March 1, 2022 | seekingalpha.com

Fennec Pharmaceuticals GAAP EPS of -$0.18

March 1, 2022 | benzinga.com

The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of BMBL, FENC and SPWR

February 27, 2022 | benzinga.com

The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of BHG, FENC and GATO

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive FENC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Fennec Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

FENC Company Calendar

Last Earnings: 11/10/2021
Today: 8/11/2022
Fiscal Year End: 12/31/2022

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:FENC
CUSIP: N/A
CIK: 1211583
Web: www.fennecpharma.com
Phone: 919-636-4530
Fax: 919-890-0490
Employees: N/A
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $12.00
High Stock Price Forecast: $14.00
Low Stock Price Forecast: $10.00
Forecasted Upside/Downside: +70.3%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.75
Research Coverage: 4 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.63)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-17,350,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -93.74%
Return on Assets: -68.17%

Debt

Debt-to-Equity Ratio: 0.36
Current Ratio: 8.96
Quick Ratio: 8.96

Sales & Book Value

Annual Sales: $170,000.00
Price / Sales: 1,080.25
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.61 per share
Price / Book: 11.55

Miscellaneous

Outstanding Shares: 26,067,000
Free Float: 23,544,000
Market Cap: $183.64 million
Optionable: Optionable
Beta: 0.09

Key Executives

Mr. Rostislav Raykov (Age 42)
Pres, CEO & Director
Mr. Robert C. Andrade (Age 43)
Chief Financial Officer
Mr. Mark Gowland
Controller
Mr. Lei Fang
Pres of Pharstat Inc
Ms. Anne McKay (Age 64)
Regulatory Consultant

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

FENC Stock - Frequently Asked Questions

Should I buy or sell Fennec Pharmaceuticals stock right now?: 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Fennec Pharmaceuticals in the last twelve months. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" FENC shares.
View FENC analyst ratings or view top-rated stocks.
What is Fennec Pharmaceuticals' stock price forecast for 2022?: 4 Wall Street analysts have issued 1 year price targets for Fennec Pharmaceuticals' stock. Their FENC share price forecasts range from $10.00 to $14.00. On average, they predict the company's share price to reach $12.00 in the next twelve months. This suggests a possible upside of 74.4% from the stock's current price.
View analysts price targets for FENC or view top-rated stocks among Wall Street analysts.
How have FENC shares performed in 2022?: Fennec Pharmaceuticals' stock was trading at $4.40 on January 1st, 2022. Since then, FENC stock has increased by 56.4% and is now trading at $6.88.
View the best growth stocks for 2022 here.
How were Fennec Pharmaceuticals' earnings last quarter?: Fennec Pharmaceuticals Inc (NASDAQ:FENC) released its quarterly earnings data on Wednesday, November, 10th. The company reported ($0.16) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.17) by $0.01.

What other stocks do shareholders of Fennec Pharmaceuticals own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Fennec Pharmaceuticals investors own include Dynavax Technologies (DVAX), Sorrento Therapeutics (SRNE), Pfizer (PFE), Amarin (AMRN), VBI Vaccines (VBIV), Gilead Sciences (GILD), Trevena (TRVN), Aldeyra Therapeutics (ALDX), Coherus BioSciences (CHRS) and Exelixis (EXEL).
What is Fennec Pharmaceuticals' stock symbol?: Fennec Pharmaceuticals trades on the NASDAQ under the ticker symbol "FENC."
Who are Fennec Pharmaceuticals' major shareholders?: Fennec Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional investors include JPMorgan Chase & Co. (0.03%).
View institutional ownership trends.
How do I buy shares of Fennec Pharmaceuticals?: Shares of FENC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Fennec Pharmaceuticals' stock price today?: One share of FENC stock can currently be purchased for approximately $6.88.
How much money does Fennec Pharmaceuticals make?: Fennec Pharmaceuticals (NASDAQ:FENC) has a market capitalization of $179.36 million and generates $170,000.00 in revenue each year. The company earns $-17,350,000.00 in net income (profit) each year or ($0.63) on an earnings per share basis.
How can I contact Fennec Pharmaceuticals?: Fennec Pharmaceuticals' mailing address is PO BOX 13628 68 TW ALEXANDER DRIVE, DURHAM NC, 27709. The official website for the company is www.fennecpharma.com. The company can be reached via phone at 919-636-4530 or via fax at 919-890-0490.

This page (NASDAQ:FENC) was last updated on 8/12/2022 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Fennec Pharmaceuticals - FENC Stock Forecast, Price & News

Fennec Pharmaceuticals MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Fennec Pharmaceuticals (NASDAQ:FENC) Stock

Fennec Pharmaceuticals Stock Down 0.5 %

Analysts Set New Price Targets

FENC Stock News Headlines

FENC Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

FENC Stock - Frequently Asked Questions

Should I buy or sell Fennec Pharmaceuticals stock right now?

What is Fennec Pharmaceuticals' stock price forecast for 2022?

How have FENC shares performed in 2022?

How were Fennec Pharmaceuticals' earnings last quarter?

What other stocks do shareholders of Fennec Pharmaceuticals own?

What is Fennec Pharmaceuticals' stock symbol?

Who are Fennec Pharmaceuticals' major shareholders?

How do I buy shares of Fennec Pharmaceuticals?

What is Fennec Pharmaceuticals' stock price today?

How much money does Fennec Pharmaceuticals make?

How can I contact Fennec Pharmaceuticals?

MarketBeat Resources

Premium Research Tools

Market Data and Calendars

Investing Education and Resources

Overall MarketRank^™